The Widely Used Antihelmintic Drug Albendazole is a Potent Inducer of Loss of Heterozygosity
The antihelmintic drug ABZ and its metabolites belong to the chemical family of benzimidazoles (BZM) that act as potent tubulin polymerization inhibitors, suggesting a potential re-direction of BZMs for cancer therapy. Applying UV-Vis spectrometry we here demonstrate ABZ as a DNA intercalator. This...
Saved in:
| Published in: | Frontiers in pharmacology Vol. 12; p. 596535 |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
Switzerland
Frontiers Media S.A
18.02.2021
|
| Subjects: | |
| ISSN: | 1663-9812, 1663-9812 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The antihelmintic drug ABZ and its metabolites belong to the chemical family of benzimidazoles (BZM) that act as potent tubulin polymerization inhibitors, suggesting a potential re-direction of BZMs for cancer therapy. Applying UV-Vis spectrometry we here demonstrate ABZ as a DNA intercalator. This insight led us to determine the primary mode of ABZ action in mammalian cells. As revealed by RNA sequencing, ABZ did neither grossly affect replication as analyzed by survival and replication stress signaling, nor the transcriptome. Actually, unbiased transcriptome analysis revealed a marked cell cycle signature in ABZ exposed cells. Indeed, short-term exposure to ABZ arrested mammalian cells in G2/M cell cycle stages associated with frequent gains and losses of chromatin. Cellular analyses revealed ABZ as a potent mammalian spindle poison for normal and malignant cells, explaining the serious chromosome segregation defects. Since chromosomal aberrations promote both cancer development and cell death, we determined if besides its general cytotoxicity, ABZ could predispose to tumor development. As measured by loss of heterozygosity (LOH)
in vitro
and
in vivo
ABZ was found as a potent inducer of LOH and accelerator of chromosomal missegregation. |
|---|---|
| Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 Jan Willem Van Der Laan, Medicines Evaluation Board, Netherlands This article was submitted to Predictive Toxicology, a section of the journal Frontiers in Pharmacology These authors have contributed equally to this work Edited by: Elias Georges, McGill University, Canada Reviewed by: Thavy Long, McGill University, Canada |
| ISSN: | 1663-9812 1663-9812 |
| DOI: | 10.3389/fphar.2021.596535 |